Evidence map›Paper›PMID 35179704›Full record

ArticleDrug safety2022

High-Dimensional Propensity Score-Adjusted Case-Crossover for Discovering Adverse Drug Reactions from Computerized Administrative Healthcare Databases.

Etienne Volatier, Francesco Salvo, Antoine Pariente, Émeline Courtois, Sylvie Escolano, Pascale Tubert-Bitter, Ismaïl Ahmed

Abstract read
PubMed Publisher
In one paragraph

Article in Drug safety, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Etienne VolatierCenter for Research in Epidemiology and Population Health (CESP, U1018), High-Dimensional Biostatistics for Drug Safety and Genomics Team, Inserm, Université Paris-Saclay, UVSQ, Université Paris-Sud, Villejuif, France. etienne.volatier@inserm.fr.ORCID http://orcid.org/0000-0001-6774-3376
Francesco SalvoBordeaux Population Health Research Center, Pharmacoepidemiology Team (UMR 1219), Inserm, University of Bordeaux, Bordeaux, France.
Antoine ParienteBordeaux Population Health Research Center, Pharmacoepidemiology Team (UMR 1219), Inserm, University of Bordeaux, Bordeaux, France.
Émeline CourtoisCenter for Research in Epidemiology and Population Health (CESP, U1018), High-Dimensional Biostatistics for Drug Safety and Genomics Team, Inserm, Université Paris-Saclay, UVSQ, Université Paris-Sud, Villejuif, France.
Sylvie EscolanoCenter for Research in Epidemiology and Population Health (CESP, U1018), High-Dimensional Biostatistics for Drug Safety and Genomics Team, Inserm, Université Paris-Saclay, UVSQ, Université Paris-Sud, Villejuif, France.
Pascale Tubert-Bitter *Center for Research in Epidemiology and Population Health (CESP, U1018), High-Dimensional Biostatistics for Drug Safety and Genomics Team, Inserm, Université Paris-Saclay, UVSQ, Université Paris-Sud, Villejuif, France.
Ismaïl Ahmed *Center for Research in Epidemiology and Population Health (CESP, U1018), High-Dimensional Biostatistics for Drug Safety and Genomics Team, Inserm, Université Paris-Saclay, UVSQ, Université Paris-Sud, Villejuif, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIncreasing availability of medico-administrative databases has prompted the development of automated pharmacovigilance signal detection methodologies. Self-controlled approaches have recently been proposed. They account for time-independent confounding factors that may not be recorded. So far, large numbers of drugs have been screened either univariately or with LASSO penalized regressions.

objectiveWe propose and assess a new method that combines the case-crossover self-controlled design with propensity scores (propensity score-adjusted case-crossover) built from high-dimensional data-driven variable selection, to account for co-medications or possibly other measured confounders.

methodsComparison with the univariate and LASSO case-crossover was performed from simulations and a real-data study. Multiple regressions (LASSO, propensity score-adjusted case-crossover) accounted for co-medications and no other covariates. For the univariate and propensity score-adjusted case-crossover methods, the detection threshold was based on a false discovery rate procedure, while for LASSO, it relied on the Akaike Information Criterion. For the real-data study, two drug safety experts evaluated the signals generated from the analysis of 4099 patients with acute myocardial infarction from the French national health database.

resultsOn simulations, our approach ranked the signals similarly to the LASSO and better than the univariate method while controlling the false discovery rate at the prespecified level, contrary to the univariate method. The LASSO provided the best sensitivity at the cost of larger false discovery rate estimates. On the application, our approach showed similar performances to the LASSO and better performances than the univariate method. It highlighted 43 signals out of 609 drug candidates: 22 (51%) were considered as potentially pharmacologically relevant, including seven (16%) regarded as highly relevant.

conclusionsOur findings show the interest of a propensity score combined with a case-crossover for pharmacovigilance. They also confirm that indication bias remains a challenge when mining medico-administrative databases.

Indexed as

Drug-Related Side Effects and Adverse ReactionsDatabases, FactualDelivery of Health CareHumansPharmacovigilancePropensity Score

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.